Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23-Reference-Cited by-同舟云学术

Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23

Published:2021-07-13 Issue:6 Volume:39 Page:1066-1075
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Ito Nobuaki^ORCID,Kubota Takuo,Kitanaka Sachiko,Fujiwara Ikuma,Adachi Masanori,Takeuchi Yasuhiro,Yamagami Hitomi,Kimura Takehide,Shinoda Tatsuya,Minagawa Masanori,Okazaki Ryo,Ozono Keiichi,Seino Yoshiki,Fukumoto Seiji

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00774-021-01250-1.pdf

Reference42 articles.

1. Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, Sugimoto T, Takeuchi Y, Matsumoto T (2015) Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. J Bone Miner Metab 33:467–473

2. Fukumoto S, Yamashita T (2007) FGF23 is a hormone regulating phosphate metabolism—unique biological characteristics of FGF23. Bone 40:1190–1195

3. Fukumoto S, Martin TJ (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20:230–236

4. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663

5. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: Proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235–1239

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders;Current Opinion in Endocrinology, Diabetes & Obesity;2024-05-01

2. A Novel Pathogenic Variant in <i>Fibroblast Growth Factor 23</i> outside the Furin-Recognizing RXXR Motif in an Autosomal Dominant Hypophosphatemic Rickets Patient;Hormone Research in Paediatrics;2024-03-15

3. Prevalence of FGF23 elevation in patients with hypophosphatemia;Clinica Chimica Acta;2024-02

4. Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia;Bone Reports;2023-06

5. Levels of FGF-23, C-Reactive Protein, Alkaline Phosphatase as A Risk Factor for Renal Osteodystrophy in Chronic Kidney Disease Patients Stage IV-V;European Journal of Medical and Health Sciences;2023-04-19